CagriSema Who Should (and Shouldn’\”t) Take It: Eligibility & Contraindications

Introduction

CagriSema is the fixed-dose combination of cagrilintide 2.4 mg, a long-acting amylin analogue, and semaglutide 2.4 mg, the GLP-1 receptor agonist already approved as Wegovy®. Novo Nordisk reported the phase 3 REDEFINE 1 results in March 2025, showing 22.7% mean weight loss at 68 weeks in adults with obesity. That is the headline number that has people asking whether they can take it.

Approval is still pending as of mid-2026, so the eligibility rules below reflect the protocol used in REDEFINE 1, REDEFINE 2 (type 2 diabetes), and REDEFINE 3 (cardiovascular outcomes), plus the standard contraindications carried over from semaglutide and cagrilintide individually. If approval lands, expect the FDA label to mirror Wegovy on most safety points and add the amylin-specific items from cagrilintide.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What BMI Cutoff Did the REDEFINE Trials Use?

REDEFINE 1 used BMI 30 kg/m squared or higher with no other requirement, or BMI 27 to 29.9 with at least one weight-related condition like hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. That matches the Wegovy label exactly and is the threshold any chronic weight management drug uses in the US.

Quick Answer: REDEFINE 1 enrolled adults with BMI 30+, or BMI 27+ with one weight-related comorbidity, the standard chronic weight management threshold

The trial recruited 3,417 participants across 11 countries with a mean starting BMI of 37.4. Baseline weight averaged 106.9 kg. Mean age was 47, and 65% were women. That demographic skew matters when you’\”re extrapolating eligibility to your own situation, because most safety signals were generated in middle-aged women with class 2 obesity.

If you’\”re under BMI 27, no phase 3 trial supports CagriSema for you. Off-label use at lower BMI is possible once approved, but the risk-benefit profile flips fast when you don’\”t have much fat to lose.

Who Is Absolutely Barred From CagriSema?

The hard contraindications carry over from semaglutide and include any personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This goes back to the rodent C-cell tumor signal seen with all long-acting GLP-1 agonists. The relevance to humans is still debated, but the FDA boxed warning is unambiguous.

Hypersensitivity to semaglutide, cagrilintide, or any inactive ingredient is also an absolute bar. Anaphylaxis with semaglutide has been reported in postmarketing data, and cross-reactivity inside the same drug family is plausible.

Pregnancy is the third absolute. Animal studies with semaglutide showed embryofetal harm. The Wegovy label requires discontinuation at least 2 months before a planned pregnancy because of the long half-life (around 1 week). Cagrilintide has a similar weekly profile. If you’\”re pregnant or trying, CagriSema is not an option.

Does a History of Pancreatitis Disqualify You?

Yes, in practical terms. REDEFINE 1, 2, and 3 excluded participants with a history of acute or chronic pancreatitis. Postmarketing reports for semaglutide include acute pancreatitis, sometimes hemorrhagic or necrotizing. With CagriSema you’\”re stacking semaglutide on top of amylin, so most prescribers will be conservative.

If you had a single episode of mild gallstone pancreatitis 10 years ago and have been symptom-free since, your endocrinologist might still prescribe with monitoring. If you have recurrent or idiopathic pancreatitis, the answer is no. Persistent severe abdominal pain radiating to the back, sometimes with vomiting, is the red flag to discontinue immediately and seek care.

Triglycerides above 500 mg/dL also raise the bar, since hypertriglyceridemia is itself a pancreatitis trigger. Many clinicians will want lipids controlled first.

What About Type 1 Diabetes and Other Diabetic Conditions?

Type 1 diabetes was excluded from all three REDEFINE trials. CagriSema’\”s amylin component matters here, because endogenous amylin is co-secreted with insulin from beta cells. Type 1 patients have essentially no amylin reserve, so the pharmacology is different from what was studied. Until trials specifically test this group, T1D is a no.

Type 2 diabetes is included. REDEFINE 2 enrolled 1,206 adults with T2D and obesity, with a mean baseline HbA1c around 8.4%. Topline results released in 2025 showed strong A1c reduction alongside 13.7% weight loss, slightly less than the obesity-only trial because diabetes patients consistently lose less weight on GLP-1s.

Diabetic gastroparesis is a real concern. Both semaglutide and cagrilintide slow gastric emptying. Stacking them in a patient who already has delayed emptying can produce severe nausea, food retention, and aspiration risk during anesthesia. Most prescribers will not start CagriSema in known gastroparesis.

Kidney and Liver Function: Where Are the Cutoffs?

REDEFINE excluded eGFR under 30 mL/min/1.73m squared. Semaglutide itself doesn’\”t require dose adjustment for renal impairment in the FDA label, but severe dehydration from GLP-1 side effects can worsen acute kidney injury. Cagrilintide hasn’\”t been studied in advanced CKD. Practical threshold for prescribing once approved: eGFR 30 or higher, with hydration counseling and labs every 3 months in stage 3 CKD.

Liver disease is more permissive. Mild to moderate hepatic impairment (Child-Pugh A or B) wasn’\”t an exclusion. Severe impairment (Child-Pugh C) was excluded because the drugs haven’\”t been studied there. MASH and MASLD are not disqualifying. Semaglutide showed liver benefit in the ESSENCE phase 3 MASH trial reported in 2024, and CagriSema is being studied in this space too.

Are There Age-related Restrictions?

REDEFINE 1 enrolled adults 18 and older with no upper age cap. Mean age was 47 with a standard deviation of 12 years, so the bulk of safety data sits between 35 and 60. Patients over 75 were underrepresented, fewer than 5% of the trial. Frailty, sarcopenia, and falls become real concerns at higher ages because GLP-1 weight loss is roughly 30 to 40% lean mass.

Pediatric use is off the table. There are no phase 3 CagriSema trials in adolescents. Wegovy got an FDA expansion to ages 12 and up in 2022 based on the STEP TEENS trial, but cagrilintide hasn’\”t been studied in kids. Don’\”t expect a pediatric indication for CagriSema for at least 3 years post-approval.

Drug Allergies and Prior GLP-1 Intolerance: What Counts?

If you had severe nausea, vomiting, or persistent GI symptoms on semaglutide alone that didn’\”t resolve after 8 to 12 weeks of titration, CagriSema is unlikely to feel better. The amylin component independently slows gastric emptying. Many of the worst GI complaints from the REDEFINE 1 trial came from patients who escalated too fast.

If you developed pancreatitis, gallbladder disease, or an allergic reaction on a prior GLP-1, CagriSema is contraindicated. The class effect carries.

If you tolerated semaglutide but plateaued in weight loss, you’\”re an ideal candidate. The REDEFINE 1 design was built around the hypothesis that adding amylin restores efficacy when GLP-1 alone runs out of headroom.

Key Takeaway: Pregnancy, planned pregnancy within 2 months, and breastfeeding are exclusions; semaglutide has a known washout period

What Screening Should Happen Before Starting?

A reasonable pre-CagriSema workup includes: BMI confirmation, vitals, complete metabolic panel including eGFR and liver enzymes, fasting lipids, HbA1c, TSH if not done in the last year, pregnancy test for women of childbearing age, and a careful history of pancreatitis, thyroid cancer, MEN 2, gastroparesis, and gallbladder disease.

For TrimRx patients exploring eligibility, the free assessment quiz captures most of these data points up front, and the prescribing clinician flags anything that needs further workup before issuing a personalized treatment plan. CagriSema isn’\”t available yet as a compounded option because the FDA hasn’\”t approved the brand, but knowing whether you’\”d qualify is useful for planning.

How Does CagriSema Eligibility Compare to Wegovy or Zepbound®?

Largely the same. The BMI thresholds match. Thyroid history, pancreatitis, pregnancy, and severe renal impairment exclude you from all three. Differences sit at the margins. Wegovy has the most postmarketing data, so prescribers know what bumps look like over 3-plus years. Zepbound has stronger weight loss numbers (20.9% at 72 weeks in SURMOUNT-1, Jastreboff et al. 2022 NEJM) but a similar exclusion list. CagriSema appears to land between them on efficacy, with REDEFINE 1 showing 22.7% versus Wegovy’\”s 14.9% in STEP 1 (Wilding et al. 2021 NEJM).

The tolerability profile in REDEFINE 1 was slightly worse than semaglutide alone, with more nausea and vomiting in the early weeks but a similar discontinuation rate around 6%.

What If You Have Obstructive Sleep Apnea or Heart Failure?

Both are pluses, not minuses. SURMOUNT-OSA led to a tirzepatide FDA approval for moderate-to-severe OSA in December 2024, and CagriSema is being studied in the same space because weight loss treats the underlying cause. Sleep apnea makes you a stronger candidate, not a weaker one.

Heart failure with preserved ejection fraction (HFpEF) was the indication for STEP-HFpEF (semaglutide), where weight loss improved symptoms and exercise capacity. REDEFINE 3 is testing CagriSema for MACE reduction in patients with established cardiovascular disease. If approved with a cardiovascular indication, CagriSema could become a first-line option for the obese-plus-CVD patient.

How Do Clinicians Decide If You’\”re a Good Candidate Beyond the Eligibility Checklist?

The hard contraindications are easy. The judgment calls are harder. A 52-year-old with BMI 31, well-controlled hypertension, mild fatty liver, and a sister with type 2 diabetes is a clear yes. A 28-year-old with BMI 28 who wants to lose 10 pounds for a wedding and has no comorbidities is a clear no, even though she technically meets the BMI 27 plus comorbidity threshold if you stretch the definition.

Between those extremes sits most of the patient population. The factors that push toward prescribing include: prior weight loss attempts (5-plus serious tries via diet, exercise, or other meds), clear health consequences of current weight (sleep apnea, joint pain, prediabetes, lipid issues), and a stated multi-year commitment to using the drug as part of a broader plan. The factors that push against include: very low BMI for the threshold, history of eating disorders (anorexia, bulimia), unrealistic expectations (wanting to lose 50% of body weight in 6 months), and unwillingness to maintain treatment indefinitely.

Eating disorder history deserves specific attention. Active anorexia nervosa is a contraindication. Past anorexia in remission requires careful evaluation because GLP-1s can trigger relapse by removing the hunger signals that drive recovery. Binge eating disorder is more complicated: some patients do extremely well on GLP-1s because the medication blunts the urge to binge, but others find the appetite suppression itself triggers restriction patterns. Discuss your full history with the prescriber.

What Ongoing Monitoring Do CagriSema Patients Need?

The standard protocol from the SUSTAIN and STEP programs translates directly. Expect office visits or telehealth check-ins at week 4, week 12, week 24, and then every 3 to 6 months for as long as you’\”re on the drug. Baseline labs include complete metabolic panel, lipid panel, HbA1c, and TSH. Recheck CMP and A1c at 12 weeks and 6 months.

Vitals matter. Blood pressure typically falls 5 to 8 mmHg by 6 months. Patients on antihypertensives often need dose reductions. Heart rate may rise 2 to 5 bpm on GLP-1s, which is rarely clinically significant but worth tracking.

Watch for the rare but serious events: persistent severe abdominal pain (pancreatitis or gallbladder disease), severe upper right quadrant pain (gallstones), unexplained neck swelling (extremely rare thyroid signal), severe persistent vomiting, and signs of dehydration including acute kidney injury markers on labs.

Bottom line: Severe gastroparesis, active gallbladder disease, and eGFR under 30 are practical disqualifiers

FAQ

Can I Take CagriSema If I Had Bariatric Surgery?

It hasn’\”t been studied formally in post-bariatric patients, but the practical answer is: probably yes, with caution. GLP-1s plus amylin both slow gastric emptying, which can worsen dumping syndrome in some sleeve gastrectomy or bypass patients. Start at the lowest dose and escalate slower than the standard protocol.

Does Taking Thyroid Medication for Hypothyroidism Disqualify Me?

No. Levothyroxine for primary hypothyroidism is fine. The thyroid contraindication is specifically for medullary thyroid cancer and MEN 2, both of which are rare hereditary conditions. Routine hypothyroidism on stable levothyroxine isn’\”t a barrier.

Can I Take CagriSema While on Antidepressants or ADHD Meds?

Yes, no major interactions are expected. SSRIs, SNRIs, bupropion, and stimulants don’\”t share metabolism pathways with semaglutide or cagrilintide. Watch for additive GI side effects with SSRIs, since both can cause nausea early on.

Is There an Age Cap?

Not in the trial protocol, but practical experience suggests caution above 75. Lean mass loss, fall risk, and dehydration risk all rise with age. If you’\”re 75-plus with sarcopenia, weight loss meds aren’\”t usually first-line.

What If I’\”m Breastfeeding?

CagriSema is contraindicated during breastfeeding. Semaglutide’\”s passage into breast milk hasn’\”t been adequately characterized in humans, and the long half-life means infant exposure could persist. Wait until you’\”ve fully weaned.

Can I Qualify If My BMI Is 26 but I Have Diabetes?

For type 2 diabetes specifically, the GLP-1 class is often prescribed at BMI under 27, but CagriSema’\”s weight management indication will likely require BMI 27-plus with comorbidity or BMI 30-plus. Once approved for T2D specifically, the BMI threshold may be lower for the diabetes indication.

How Do I Find Out If I’\”m Eligible Without a Doctor’\”s Visit?

A telehealth assessment is the fastest route. TrimRx’\”s free assessment quiz screens for the major contraindications and your clinician reviews labs and history before recommending a treatment path. Once CagriSema is FDA-approved, eligibility screening will mirror what’\”s already done for semaglutide and tirzepatide.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Related Articles

• Semaglutide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications
• Orforglipron Who Should (and Shouldn’t) Take It: Eligibility & Contraindications
• Tirzepatide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications
• Mazdutide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications